ArticlePharmacology research & perspectives2025

Correction to "The MAO-B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti-Androgen and Cytostatic Agents".

No numbers read from the abstract.

Not cited yet